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Aims Duchenne muscular dystrophy (DMD) is a severe and still incurable disease, with heart failure as a leading cause of
death. The identiﬁcation of a disease-modifying therapy may require early-initiated and long-term administration, but
such type of therapeutic trial is not evident in humans. We have performed such a trial of SNT-MC17/idebenone in
the mdx mouse model of DMD, based on the drug’s potential to improve mitochondrial respiratory chain function
and reduce oxidative stress.
Methods
and results
In this study, 200 mg/kg bodyweight of either SNT-MC17/idebenone or placebo was given from age 4 weeks until 10
months in mdx and wild-type mice. All evaluators were blinded to mouse type and treatment groups. Idebenone
treatment signiﬁcantly corrected cardiac diastolic dysfunction and prevented mortality from cardiac pump failure
induced by dobutamine stress testing in vivo, signiﬁcantly reduced cardiac inﬂammation and ﬁbrosis, and signiﬁcantly
improved voluntary running performance in mdx mice.
Conclusion We have identiﬁed a novel potential therapeutic strategy for human DMD, as SNT-MC17/idebenone was cardiopro-
tective and improved exercise performance in the dystrophin-deﬁcient mdx mouse. Our data also illustrate that the
mdx mouse provides unique opportunities for long-term controlled prehuman therapeutic studies.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Duchenne muscular dystrophy (DMD) is the most common and
devastating type of muscular dystrophy worldwide, affecting one
in 3500 live male births.
1 This progressive and lethal X-linked
myopathy is characterized by deﬁciency of dystrophin, a subsarco-
lemmal protein critical in membrane stabilization and prevention of
contraction-induced cell membrane damage. Progressive striated
muscle weakness and cardiomyopathy lead to severe disability
and mortality of patients in their late teens to early twenties.
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European Heart Journal (2009) 30, 116–124
doi:10.1093/eurheartj/ehn406Following implementation of ventilatory assistance to treat respir-
atory failure, heart failure has become a leading cause of death in
DMD.
2,3 In young DMD patients with still normal cardiac ventricu-
lar function at rest, reduced left ventricular contractile reserve
(determined by inotropic stimulation with dobutamine) predicts
later decline in cardiac function with age.
4
Causative gene identiﬁcation and pathophysiological insights
have fuelled increasing therapeutic research efforts for DMD, of
which the vast majority has been focused on the skeletal muscle
involvement. Nevertheless currently no effective treatment
exists, only corticosteroids have proved of some beneﬁt but
their long-term use is hampered by signiﬁcant adverse effects. A
major lesson from performed human trials that aimed to identify
a disease-modifying treatment for DMD seems to be their appar-
ently inevitable methodological shortcomings. Indeed, it is
logic that the identiﬁcation of a disease-modifying compound
may require early-initiated (i.e. before onset of pathology) and
long-term administration, but such type of therapeutic trial is not
evident in human patients. We have performed such a trial of
idebenone in the homologous dystrophin-deﬁcient mdx mouse
model of DMD,
5 based on the drug’s potential to improve mito-
chondrial respiratory chain function and cellular energy production,
as well as its potency to reduce oxidative stress.
6,7 It was anticipated
that early-initiated and long-term idebenone-mediated blocking of
these important downstream effectors of dystrophin-deﬁciency
would result in a reduced disease state in treated mdx mice at old
age. Other than facilitating presymptomatic initiation and veritable
long-term administration of treatment, the mouse model allowed
invasive in vivo haemodynamic studies for the assessment of cardiac
contractility. Limitations of the study were the required use of anaes-
thesia (for cardiac assessments) and the multiple endpoint testing.
Methods
Animals
Male wild-type (C57BL/10ScSn) and dystrophin-deﬁcient mdx (C57BL/
10ScSn-Dmd
mdx/J) mice obtained from Jackson Laboratories were
maintained at RCC Laboratory Services (Fu ¨llinsdorf, Switzerland).
Sedentary mice (for cardiac assessments at age 10 months) from
one litter were housed together from weaning to the end of the
study period. Mice used for voluntary wheel running assessments
(exercised mice) were housed individually in wheel cages from
weaning to the end of the study period. All mice were kept under arti-
ﬁcial light from 5 am to 5 pm and in darkness from 5 pm to 5 am
throughout their life span. All procedures were performed in accord-
ance with the Belgian and Swiss regulations and under the required
licenses, approval of procedures was obtained from the KU Leuven
committee on the use and care of animals.
Treatment protocol, treatment groups,
and ﬂow of animals
The molecule investigated in this study is idebenone: 2,3-dimethoxy-
5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (research code: ‘SNT-
MC17’; International non-proprietary name (INN): ‘idebenone’). A dose
of 200 mg/kg bodyweight of either idebenone (‘ide’: SNT-MC17 from
Santhera Pharmaceuticals, Liestal) or vehicle (‘veh’; placebo) was given
once daily by gavage from the age of 4 weeks until the age of 10
months in mdx (‘mdx-ide’ group, n ¼ 18; ‘mdx-veh’ group, n ¼ 14) and
wild-type mice (‘wt-veh’ group, n ¼ 10). For wheel running performance
(exercised mice), similar groups were treated from age 3 weeks until 12
weeks (wt-veh, n ¼ 8; mdx-veh, n ¼ 10; mdx-ide, n ¼ 17). Animals were
randomized per cage to the treatment groups. Litters of breeding cages
were randomized to placebo (vehicle) and idebenone in an alternate
fashion. All animals were included in the study between 17 April 2005
and 29 May 2005 (42 days). Vehicle consisted of 0.5% carboxymethylcel-
lulose sodium salt (CMC, Fluka, Buchs, Switzerland) in water. To ensure
accurate dosing of animals, idebenone was administered by gavage
rather than by food mix. Since it was only feasible to administer animals
once a day, a dose of 200 mg/kg/day was chosen as it represented a
dose similar to the highest exposed animals (mice) in a therapeutic
study in frataxin-deﬁciency.
8 During the course of the study one animal
in the mdx-veh group died around 7 months and one animal in the
wt-veh group had to be killed at 6 months due to a tumor-like swelling
in the abdomen. From one animal in the mdx-ide group there were no
serum-derived measurements (cardiac biomarkers) available at baseline
as the serum sample was lost in process. For the cardiac haemodynamic
data assessments at age 10 months, three experiments were excluded
because of technical reasons (problems with catheter insertion; two
animals from mdx-ide group, one animal from wt-veh group), and one
experiment was excluded because of a technical complication (liver
tear) with haemodynamic instability (one animal in mdx-veh group).
All animals allocated to the wheel running experiment completed
the experiment.
Echocardiography at age 10 months
Mice were anaesthetized by 2% isoﬂurane inhalation. After shaving
their chest, the animals were positioned in a left decubitus position
on a heating pad for body temperature maintenance. Animals were
imaged using a Vivid7 Dimensions (GE Vingmed, Horten, Norway)
equipped with a 96-element linear array transducer (i13L) transmitting
at 14 MHz. Standard gray scale M- and B-mode images were acquired
using a parasternal long- and short-axis view. Grayscale measurements
were made off-line on a dedicated workstation (EchoPac, GE
Vingmed). End-diastolic and end-systolic wall thickness of the antero-
septal (IVS) and inferolateral (PW) wall segments were measured
together with the end-diastolic and end-systolic left ventricular internal
diameter on both the M- and B-mode acquisitions from which frac-
tional shortening (FS) was derived. From the average of the M- and
B-mode assessment of ventricular morphology, LV myocardial volume
(LVV), LV end-diastolic (EDV) and end-systolic (ESV) volumes were cal-
culated using a half ellipsoid model of the LV. In this model, the long-axis
dimension of the individual heart was taken into account by measuring it
on the long-axis images. From these volumes LV ejection fraction (EF)
was calculated. Finally, anteroseptal and inferolateral wall thickening
was calculated as the change in thickness relative to the end-diastolic
thickness and expressed as a percentage. All data were collected and
analysed by two independent observers blinded to mouse type and ran-
domization. For all measurements, the average value of both observers
was used for statistical analysis.
In vivo cardiac haemodynamic measurements
at age 10 months
Following anaesthesia for echocardiography, mice were allowed to
recover completely for at least 3 days prior to haemodynamic assess-
ment of cardiac contractility. For this, anaesthetized mice (intraperito-
neal urethane 1200 mg/kg and alfa-chloralose 50 mg/kg) were
tracheotomized and mechanically ventilated (Minivent 845; Hugo
Sachs/Harvard Apparatus, March-Hugstetten, Germany). Body temp-
erature was monitored with a rectal probe and maintained at 378C
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conductance catheter (1.4 Fr, SPR-839; Millar Instruments, Houston,
TX) was inserted in the right carotid artery and advanced into the LV
to measure instantaneous intraventricular pressure and volume
(PV-loops).
9,10 After stabilization, baseline haemodynamic data were
recorded. Subsequently LV preload was decreased by transient inferior
caval vein occlusion (with cotton swab) while PV-loops (occlusion
loops) were recorded, allowing to derive load-independent (intrinsic)
contractility parameters. Afterwards, dobutamine was infused
through a right jugular vein catheter at incremental doses of 1, 3, 10,
and 30 ng/g/min each time for 2 min until a stable heart rate plateau
was reached. During progressive dobutamine exposure, PV loops
were recorded (allowing determination of contractile reserve). Next
the dobutamine dose was stepwise reduced from 30 to 10 to 3 and
to 1 ng/g/min, and each time occlusion loops were recorded. The
parallel conductance attributed to tissues surrounding the LV cavity
was estimated by bolus injection of 1.5 ml of 30% NaCl into the
jugular vein. Blood conductance was determined at the end of each
experiment using three precalibrated cuvettes, a conductance-volume
calibrationlinewasconstructed withthese cuvet data. Analysiswasper-
formed from each experiment with correction for parallel volume, and
datawereexpressedinabsolutevolumes(PVANsoftware,MillarInstru-
ments). All dataarethe average of at least ﬁvemeasurementsduring the
experiment, each measurement representing at least 10 successive
loops.Onlytechnicallyacceptableloops(noarrhythmia,stablebaseline)
wereincludedintheanalysisforeachexperiment,whichwasperformed
blinded to mouse type and treatment groups.
Cardiac histology at age 10 months
After cardiac catheterizations, the animals were sacriﬁced, the hearts
removed and ﬁxed in a 6% formalin solution. The ventricles were cut
into four slices parallel to the basis of the heart, and embedded in
parafﬁn. Four-micron-thick histological sections were prepared in a
standard way and stained with H&E and with Masson’s trichrome for
collagen. Sections were examined by light microscopy for the
presence of inﬂammation and ﬁbrosis, blinded to mouse type and treat-
mentgroups.TheRV,andtheseptum,theanterior,lateralandposterior
wall of the LV were assessed separately. The proportion of ﬁbrosis was
quantiﬁed by a conventional point counting method.
11 For each area, a
total of 250 points were counted in three random ﬁelds, and the results
were expressed as the proportion (in%) of the points hitting ﬁbrosis.
The amount of inﬂammation was scored from 0 (absent) to 3 (most
severe case in our series) in ﬁve random ﬁelds per area. An average
value was also calculated.
Striated muscle histology at age 10 months
The ﬁbre diameter variability (minimal Feret’s diameter variance
coefﬁcients) and the percentage of centralized nuclei in the diaphragm
and the quadriceps muscle were analysed as previously described.
12
Cardiac biomarkers
Cardiac troponin I (cTnI) levels were analysed in blood serum using
the High Sensitivity Mouse Cardiac troponin-I Elisa Kit (Life Diagnos-
tics, West Chester, USA). Blood samples were serially taken at ages
1, 6, and 10 months (retro-orbital sinus/plexus sampling; sample
volume 150 mL).
Computerized wheel running analysis
Voluntary exercise performance was monitored in parallel groups of
mice from the age of 29 days (after 1 day acclimation to the monitor-
ing equipment) until age 12 weeks. Voluntary running activity was
measured with a computerized wheel system essentially as described
previously.
13 Wheel revolution counts were recorded every 10 s.
Since all mice run extensively during the night and showed only
little and irregular daytime running, only night-time running was
included into the analysis. Beside the total daily running distance, a
subset of running events (10 s time windows) with a wheel revolution
above a speed threshold equivalent to 1.75 km/h was analysed
separately.
Statistical analyses
(i) Echocardiography and cardiac haemodynamic measurements:
Analysis was performed using Statistica 7.1, with Kruskal–Wallis
ANOVA and x
2 for post-hoc analyses (including Bonferroni adjust-
ments).
14 For the comparison of haemodynamic parameters at base-
line (non-stress) conditions that could predict mortality during
dobutamine stress Mann–Whitney U tests were used. (ii) Cardiac his-
tology: In order to take into account the correlated nature of the data
a ﬁrst-order Generalized Estimating Equation (GEE) approach was
employed using independent and exchangeable working correlations
matrices. Marginal binary and ordinal logistic regression models were
considered for the analysis of ﬁbrosis and inﬂammation, respectively.
For the analysis of inﬂammation, different models for ordinal data
were intended. However, only proportional odds models were poss-
ible to be ﬁtted due to sparseness of the sample. In each of the
ﬁtted models, the effect of the group, area, and group area inter-
action term were included. The evaluation of the effect of the
factors in the model was performed by using the Score-test for type
3 GEE analysis. Bonferroni adjustments to the signiﬁcance levels for
pairwise comparisons were performed when signiﬁcant differences
were found with the Score-test. Analyses were performed using SAS
(9.1 for Windows). The GEE models were ﬁtted using the procedure
PROC GENMOD. (iii) Wheel running data: Analysis of the wheel
running data (daily running distance, high speed running distance) integrat-
ing the whole analysed time period was done with a two-way ANOVA
using the ‘aov’ method in the S-Plus software and with adapted (Bonfer-
roni adjustment) signiﬁcance levels for pairwise comparisons.
Results
In vivo cardiac haemodynamics at age
10 months: idebenone prevents
diastolic dysfunction
Theresultsofthecomparisonofthehaemodynamicvariables(under
baseline conditions) between the different treatment groups at age
10 months are shown in Table 1. The heart weight (corrected for
tibial length) was signiﬁcantly higher in both mdx groups compared
with the wild-type group, implying cardiac hypertrophy in mdx
mice that was not corrected by idebenone treatment. Heart rates
were similar in placebo-treated wild-type and mdx groups, but
were higher in the idebenone treated mdx group. End-diastolic
pressure, a measure of heart failure, was signiﬁcantly increased in
the placebo-treated mdx group, and corrected to wild-type levels
in the idebenone-treated mdx group. In idebenone-treated mdx
mice isovolumetric relaxation during diastole (Tau) was signiﬁcantly
faster than in placebo-treated mdx mice, and comparable with wild-
type levels. Other load-dependent and -independent contractility
measures under baseline conditions showed no further signiﬁcant
differences between the different groups.
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cardiac failure in 10 month old mdx mice
Following baseline haemodynamic assessments, a dobutamine
stress test was applied to assess cardiac contractile reserve (detec-
tion of subclinical cardiac failure) in the different treatment groups.
Upon progressive challenge with the b-adrenergic receptor agonist
dobutamine (incremental doses of 1, 3, 10, and 30 ng/g/min),
already at low dobutamine doses placebo-treated mdx mice
showed a 58% (7/12) mortality rate due to acute cardiac decom-
pensation (Figure 1; lethal dobutamine doses: 1 ng/g/min for n ¼
3, 10 ng/g/min for n ¼ 3, and 30 ng/g/min for n ¼ 1). This cardiac
failure was manifested by abrupt left ventricular dilatation and
decreasing LV systolic pressures, and was not preceded by arrhyth-
mias, indicating a primary heart failure based on diminished con-
tractility. Cardiac pump failure during the dobutamine stress test
was signiﬁcantly prevented in mdx mice that had been treated
with idebenone (Figure 1; reduction of heart failure and mortality
to 19%, P ¼ 0.03).
Given the pronounced differences in cardiac contractile reserve
and mortality rate between idebenone- and placebo-treated mdx
mice, we wanted to ﬁnd parameters at baseline (non-stress)
conditions that could predict mortality during the dobutamine
stress test. Differences in all measured haemodynamic variables
were analysed for mice that survived the stress test (pooled surviv-
ing animals from WT-veh, mdx-veh, and mdx-ide groups) vs.
placebo-treated mdx mice that did not survive the stress test
(Table 2). Non-surviving mdx-veh mice had a higher heart weight
(cardiac hypertrophy) and showed reduced diastolic and systolic
contractility at baseline conditions. Reduced values for the load-
independent parameters PAMP (preload adjusted maximal
power), Ees (end-systolic elastance), and PRSW (preload recruita-
ble stroke work) in non-surviving mice indicate that it is a reduced
intrinsic myocardial contractility that predicts lethal cardiac failure
during dobutamine challenge.
Echocardiographic ﬁndings at age
10 months
The cardiac status of mdx and wild-type mice that had been long-
term treated with placebo or idebenone was also evaluated by
murine echocardiography at age 10 months (data summarized in
Table 3). Morphological assessments showed signiﬁcant differences
(ANOVA) for end-diastolic diameters for the mdx mice. In mdx
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 1 Comparison of haemodynamic parameters (mean+ + + + +SD) for wild-type vehicle-treated, mdx vehicle-treated, and
mdx idebenone-treated mice at age 10 months
WT-veh n 5 8 mdx-veh n 5 12 mdx-ide n 5 16 ANOVA P-value
HW/TL (mg/cm) 72.2+8.6 82.5+8.8* 83.5+9.9* 0.022
Parameters in steady state
HR (b.p.m.) 501+37 483+36 532+48** 0.015
Pmax (mmHg) 82.6+7.5 80.6+8.7 84.3+11.8 0.621
Pes (mmHg) 73.7+10.8 72.2+9.5 77.7+12.6 0.423
Ped (mmHg) 3.6+1.4 5.4+2.2* 3.4+1.3** 0.013
Ved (mL) 30.1+11.4 32.0+7.5 32.1+11.0 0.887
SV (mL) 16.1+5.8 15.8+3.6 15.9+6.1 0.990
EF (%) 53.2+11.7 47.6+9.8 48.1+11.1 0.483
CO (mL/min) 8149+3189 7599+1703 8639+3846 0.689
SW (mmHgmL) 1096+445 1021+367 1159+612 0.775
Ea (mmHg/mL) 5.6+3.8 4.8+1.0 5.5+2.0 0.630
dP/dtmax (mmHg/s) 6349+1005 5907+1623 7466+3099 0.209
dP/dtmin (mmHg/s) 26257+777 25564+1321 26696+1692 0.128
Tau (ms) 6.3+0.9 7.0+1.0 6.0+0.9** 0.032
Parameters obtained after temporary preload reduction
PAMP (mW/mL
2)8 8 +50 62+27 76+41 0.325
Ees (mmHg/mL) 8.4+0.9 8.0+1.1 8.2+1.2 0.721
PRSW (mmHg) 71.4+8.3 70.1+13.8 70.7+14.9 0.978
EDPVR (mmHg/mL) 0.30+0.17 0.42+0.20 0.35+0.14 0.260
dP/dt_EDV (mmHgmL/s) 303+91 359+203 296+81 0.456
PVA (mmHgmL) 1328+472 1310+584 1281+478 0.975
Efﬁciency (%) 58.1+10.3 55.2+9.8 61.3+10.7 0.310
*P , 0.05 vs. WT-veh.
**P , 0.05 vs. mdx-veh.
HW/TL indicates heart weight corrected for tibial length; HR, heart rate; Pmax, maximum pressure; Pes, end-systolic pressure; Ped, end-diastolic pressure; Ved, end-diastolic
volume; SV, stroke volume; EF, ejection fraction; CO, cardiac output; SW, stroke work; Ea, arterial elastance; PAMP, preload adjusted maximal power; Ees, end-systolic elastance;
PRSW, preload recruitable stroke work; EDPVR, end-diastolic pressure–volume relationship; PVA, pressure–volume area.
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volumes, suggesting improved diastolic ﬁlling properties.
Whereas vehicle-treated mdx mice showed a tendency towards
posterior wall hypertrophy (increased PWd), posterior wall thick-
ness in idebenone-treated mdx mice was not different from wild-
type mice although this did not reach statistical signiﬁcance (P ¼
0.095). Grayscale function comparisons showed signiﬁcant differ-
ences (ANOVA) for systolic anteroseptal wall thickening (IVS
WT, IVS WT/PW WT) in both mdx groups. This anteroseptal
wall hyperfunction in mdx mice could be compensatory for the
hypertrophic posterior wall, the heart segment that also in
human DMD is affected ﬁrst. In mdx mice idebenone treatment
showed a trend of reducing systolic anteroseptal wall thickening,
but this was not signiﬁcant (values in both mdx groups statistically
different from wild-type levels).
Histological studies at age 10 months:
idebenone reduces cardiac inﬂammation
and ﬁbrosis
Results of morphometric analysis of cardiac inﬂammation and
ﬁbrosis in 10-month-old wild-type and mdx mice (placebo or ide-
benone treated) are shown in Tables 4 and 5. For ﬁbrosis
(Table 4), GEE logistic regression analysis showed that the odd
of developing ﬁbrosis was, respectively, 15.80 (adjusted CI:
4.89–49.46, P , 0.0001) and 11.36 (adjusted CI: 3.50–35.71,
P , 0.0001) times higher in the mdx-vehicle and mdx-idebenone
groups when compared with the wild type-vehicle group. The
odd of developing ﬁbrosis was signiﬁcantly 1.39 times higher
(adjusted CI: 1.07–1.85, P ¼ 0.0062) in the mdx-vehicle com-
pared with the mdx-idebenone group. The absence of a signiﬁ-
cant group area interaction term in the models (P ¼ 0.2048
and P ¼ 0.1999 under the independent and exchangeable
model, respectively) suggests that is not possible to reject the
hypothesis of null difference in the probability of developing
ﬁbrosis among the groups across the heart areas. The
wild-type-vehicle group showed no inﬂammation whatsoever
(score 0 for all mice in all heart regions) (Table 5). Because of
that, the wild-type-vehicle group was removed from the analysis.
GEE regression analysis showed a non-signiﬁcant group area
interaction suggesting that the differences in the distribution of
inﬂammation scores between the two groups are the same
across the heart areas. The results indicate that the percentage
of subjects in high inﬂammation scores is signiﬁcantly lower
(P ¼ 0.0037) in the mdx-idebenone compared with the
mdx-vehicle group.
In skeletal muscle (quadriceps) and diaphragm, histological
assessments of ﬁbre diameter variability and percentage of ﬁbres
with centralized nuclei showed no signiﬁcant differences between
the mdx-idebenone group and the mdx-vehicle group, neither in
10-month-old sedentary mice, nor in 12-week-old exercised
(voluntary wheel running) mice (no further data shown).
Effects of idebenone on biomarkers
reﬂecting myocardial degeneration
Serum levels of cardiac Troponin I, a marker reﬂecting degree of
active myocardial degeneration, were measured in the different
treatment groups at different ages (at age 4 weeks prior to
initiation of treatment, age 6 months, age 10 months) (Table 6).
Figure 1 Idebenone signiﬁcantly improves cardiac contractile
reserve in mdx mice. Signiﬁcant differences (Kruskal–Wallis
ANOVA P ¼ 0.040) in survival rate of dobutamine stress test
protocol in 10 months old wild-type vehicle-treated, mdx vehicle-
treated, and mdx idebenone-treated mice. Non-surviving mice
died from acute heart failure based upon primary systolic con-
tractile failure.
................................................................................
Table 2 Reduced diastolic and systolic contractility at
baseline conditions (prior to inotropic challenge)
predicts cardiac failure during dobutamine stress:
comparison of baseline haemodynamic parameters
(mean+ + + + +SD) of survivors (from all treatment groups)
and non-survivors (from mdx-veh group only) of a
physiological dobutamine stress test
Survivors of full
protocol,
n 5 25
Non-survivors
(mdx-veh),
n 5 7
P-value
HW/TL (mg/cm) 78.0+9.0 86.7+9.4 0.032
Pmax (mmHg) 85.3+9.6 79.1+9.3 0.139
Pes (mmHg) 77.6+11.1 71.9+9.0 0.225
Ves (mL) 17.0+6.5 23.9+6.0 0.019
EF (%) 51.5+8.3 41.5+4.3 0.004
dP/dtmax
(mmHg/s)
7249+2487 5620+1777 0.117
dP/dtmin
(mmHg/s)
26658+1326 25302+1560 0.028
PAMP (mW/
mL
2)
85.8+39.4 45.1+13.5 0.013
Ees (mmHg/mL) 8.46+1.00 7.72+1.03 0.094
PRSW (mmHg) 73.6+11.6 64.0+12.3 0.068
Tau (ms) 6.3+0.9 7.0+1.0 0.062
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mice. Whereas cTnI levels remained low in wild-type mice at
ages 6 and 10 months, at those ages levels were strongly elevated
in mdx mice. Although at ages 6 and 10 months mean cTnI levels
were lower in the mdx-idebenone compared with the mdx-vehicle
group, indicating reduced myocardial degeneration, these differ-
ences were not statistically signiﬁcant.
Idebenone improves voluntary wheel
running performance
To evaluate if idebenone treatment improves the exercise
performance of dystrophic mdx mice, voluntary wheel running
performances of placebo (vehicle) treated wild-type mice and of
placebo treated and idebenone treated mdx mice were recorded
and analysed from the age of 29 days until age 12 weeks
(Figure 2). Compared with vehicle-treated wild-type mice, daily
running distances were signiﬁcantly lower in the vehicle-treated
mdx group. Idebenone treatment resulted in a signiﬁcant and con-
sistent improvement of daily running distances in mdx mice
(Figure 2A). Cumulative running distance analysis revealed that ide-
benone treated mdx mice (mean 298 691 m) on average ran
57 507 metres more (95% CI: 1550–113 463, t-test: P ¼ 0.045)
during the 58-day study period than vehicle-treated mdx mice
(mean 241 184 m) (Figure 2B). Further analyses revealed that
these differences in daily and cumulative running distances were
not due to differences in daily running time (data not shown),
but due to signiﬁcantly improved high speed running with idebe-
none treatment resulting in a greater distance run above a
pre-set threshold (1.75 km/h) for running speed (Figure 2C and D).
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Table 3 Comparisons of echocardiography values (mean+ + + + +SD) for wild-type vehicle-treated, mdx vehicle-treated, and
mdx idebenone-treated mice at age 10 months
WT-veh,
n 5 9
mdx-veh,
n 5 13
mdx-ide,
n 5 18
ANOVA
P-value
Morphology
IVSd (mm) 0.79+0.06 0.83+0.10 0.84+0.08 0.154
EDD (mm) 4.15+0.21 3.83+0.25* 3.9+0.29* 0.022
PWd (mm) 0.70+0.12 0.86+0.14 0.79+0.12 0.095
EDV (mL) 54.0+6.4 44.6+7.5* 47.4+8.8 0.022
LVV (mL) 45.6+3.9 47.5+5.5 47.9+5.6 0.522
Grayscale function
HR (b.p.m.) 394+79 454+76 454+86 0.252
FS (%) 24+42 9 +82 7 +4 0.158
EF (%) 56+76 3 +12 62+7 0.158
IVS WT (%) 35+75 0 +21* 46+12* 0.022
PW WT (%) 40+10 36+14 34+10 0.429
IVS WT/PW WT 0.92+0.22 1.52+0.72* 1.47+0.64* 0.023
*Different (P , 0.05) from WT-vehicle.
LV, left ventricular; IVSd, end-diastolic anteroseptal wall thickness; EDD, LVend-diastolic diameter; PWd, LV inferolateral (posterior) wall thickness; EDV, LVend-diastolic volume;
LVV, LV volume; HR, heart rate; FS, fractional shortening; EF, ejection fraction; IVS WT, LV anteroseptal wall thickening; PW WT, LV inferolateral (posterior) wall thickening.
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Table 4 Degree of cardiac ﬁbrosis (mean+ + + + +SD) in 10 month old mice [wild-type and mdx; vehicle (‘veh’) or idebenone
(‘ide) treated since age 4 weeks] (percentage of cardiac ﬁbrosis by group and cardiac area)
Area Group
WT-veh mdx-veh mdx-ide
nnn
IVS 9 0.089+0.267 13 2.677+3.838 18 2.289+2.249
LVAW 9 0.178+0.211 13 1.138+1.253 18 1.533+2.144
LVLW 9 0.044+0.133 13 0.738+1.176 18 1.444+2.852
LVPW 9 0.089+0.176 13 2.523+4.640 18 1.311+1.734
RV 9 0.222+0.406 13 3.415+1.779 18 2.467+1.560
All 45 0.124+0.253 65 2.098+2.994 90 1.809+2.160
LV, left ventricular; IVS, interventricular septum; LVAW, LV anterior wall; LVLW, LV lateral wall; LVPW, LV posterior wall; RV, right ventricle.
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The main ﬁnding of our study is that presymptomatic-initiated and
long-term idebenone treatment signiﬁcantly corrected (prevented)
cardiac diastolic dysfunction, blocked the development of
lethal acute heart failure during a dobutamine-mediated stress
protocol (improvement of contractile reserve), reduced cardiac
inﬂammation and ﬁbrosis, and improved voluntary running
performance in the dystrophin-deﬁcient mdx mouse. As such,
this study provides the ﬁrst evidence ever for a potential thera-
peutic role of idebenone in dystrophin deﬁcient muscular dystro-
phy. Whereas mice are not man and future human studies will
have to show whether therapeutic studies in a homologous
mouse model of dystrophin deﬁciency can be predictive for the
human DMD situation, the strengths of the current study are the
early initiation (in a presymptomatic stage) of treatment, its verita-
ble long-term administration (far into adulthood for the mouse),
and the extend of used in vivo outcome assessment methods
(including invasive haemodynamic measurements for cardiac con-
tractility assessment).
Limitations of this study are the required use of anaesthesia for
cardiac assessments, and the multitude of endpoints being analysed
(implying caution with the interpretation of statistically signiﬁcant
results). Whereas it seems that the anaesthesia may have
reduced left ventricular contractility during the echocardiographic
assessments (isoﬂurane anesthesia), this is expected to be only
minor or modest for the haemodynamic assessments under
urethane plus alfa-chloralose anaesthesia (as shown by the
measured load-independent parameters). Furthermore, the anaes-
thesia was identical in all treatment groups of mice, which makes it
unlikely that anaesthesia in se is a major determinant of the
observed differences between the groups. Regarding the multitude
of analysed endpoints, it was not possible for this study to have a
trial design with a predeﬁned primary outcome measure because
of insufﬁcient previous detailed knowledge about the cardiac phe-
notype in the mdx mouse.
Compared with wild-type mice, 10-month-old untreated mdx
mice (placebo group) showed signiﬁcant cardiac hypertrophy and
diastolic dysfunction, the latter being prevented by idebenone
treatment. It has been shown that acute cardiomyopathy and
heart failure can be induced by cardiovascular stressors (dobuta-
mine) in mdx mice.
15 Also, depressed cardiac contractile reserve
has been shown in DMD patients with low-dose dobutamine
stress echocardiography or angiography.
16 We therefore tested
whether an acute dobutamine stress challenge in vivo could cause
acute heart failure, and whether this phenotype could be
blocked (prevented) by idebenone. Upon challenge with dobuta-
mine, placebo-treated mdx mice developed acute cardiac decom-
pensation with a 58% mortality rate. This heart failure during
dobutamine stress was signiﬁcantly blocked in mdx mice that had
received idebenone treatment (reduction of mortality to 19%).
These ﬁndings gain further signiﬁcance from recent clinical
studies in DMD patients where dobutamine-induced alterations
in heart functions provided the single best indicator of age-related
decline in cardiac function.
4 Our further analyses revealed indi-
cations that cardiac hypertrophy and reduced intrinsic myocardial
contractility at baseline (non-stress) conditions were predictive for
lethal cardiac failure during dobutamine challenge. This indicates
that the protective ability of idebenone during stress results from
preserved ventricular contractile properties and compliance.
Besides these cardioprotective effects, we found that idebenone
treatment was associated with signiﬁcantly improved voluntary
wheel running performances (increased daily and cumulative
running distances). Remarkably, idebenone-treated mdx mice
were capable of running faster and performed longer distances
at high speed than placebo-treated mdx mice. At present it
cannot be distinguished whether the improvements in exercise
performance of these mice are linked to cardiac, skeletal muscle,
and/or other changes.
The beneﬁcial effects of idebenone can be explained by its ability
to improve mitochondrial respiratory chain function and to reduce
oxidative stress, pathways that have been implicated in the patho-
physiology of dystrophin deﬁcient muscular dystrophy. The
absence of functional dystrophin protein causes sarcolemmal
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Table 5 Degree of cardiac inﬂammation in 10 month
old mice [wild-type and mdx; vehicle (‘veh’) or
idebenone (‘ide) treated since age 4 weeks]
(distribution of inﬂammation score by group and
cardiac area)
Area Score Group
WT-veh
(n 5 9)
mdx-veh
(n 5 13)
mdx-ide
(n 5 18)
n % n % n %
IVS 0 9 100.00 0 0.00 0 0.00
1 0 0.00 6 46.15 12 66.67
2 0 0.00 6 46.15 6 33.33
3 0 0.00 1 7.69 0 0
LVAW 0 9 100.00 3 23.08 11 61.11
1 0 0.00 9 69.23 6 33.33
2 0 0.00 1 7.69 1 5.56
3 0 0.00 0 0.00 0 0.00
LVLW 0 9 100.00 6 46.15 11 61.11
1 0 0.00 4 30.77 5 27.78
2 0 0.00 3 23.08 2 11.11
3 0 0.00 0 0.00 0 0.00
LVPW 0 9 100.00 5 38.46 9 50.00
1 0 0.00 7 53.85 7 38.89
2 0 0.00 1 7.69 2 11.11
3 0 0.00 0 0.00 0 0.00
RV 0 9 100.00 0 0.00 1 5.56
1 0 0.00 3 23.08 13 72.22
2 0 0.00 10 76.92 4 22.22
3 0 0.00 0 0.00 0 0.00
All 0 45 100.00 14 21.54 32 35.56
1 0 0.00 29 44.62 43 47.78
2 0 0.00 21 32.31 15 16.67
3 0 0.00 1 1.54 0 0.00
A score of 0 equals no inﬂammation, a score of 3 equals maximal inﬂammation.
LV, left ventricular; IVS, interventricular septum; LVAW, LV anterior wall; LVLW,
LV lateral wall; LVPW, LV posterior wall; RV, right ventricle.
G.M. Buyse et al. 122instability and initiates a cascade of biochemical events in skeletal
and cardiac muscle that ultimately leads to disintegration of
muscle proteins and cell death. Impaired mitochondrial oxidative
phosphorylation and increased formation of reactive oxygen
species have been reported in mdx skeletal muscle, and oxidative
damage has been reported to be involved in the pathogenesis of
the heart failure that occurs in mdx mice.
17–19 A recent study
with mdx cardiomyocytes showed that excessive generation of
reactive oxygen species is one of the key mechanisms that link
the initial membrane fragility of the dystrophin-deﬁcient cardio-
myocyte to mitochondrial dysfunctions that precede cell death.
20
Increased oxidative stress and damage has also been reported in
human DMD patients, where interactions between the primary
genetic defect and disruptions in the normal production of free
.................................................................................................................
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Table 6 Cardiac biomarkers (cTnI; mean+ + + + +SD) in wild-type and mdx mice (vehicle or idebenone treated) at ages 1
month (prior to initiation of treatment), 6 months, and 10 months [cardiac Troponin I levels (ng/mL)]
Age Group ANOVA P-value
WT-veh mdx-veh mdx-ide
nn n
1 month 10 42+15 14 31+71 7 3 1 +8 0.7
6 months 9 42+3 13 535+177 18 392+146 0.128
10 months 9 61+8 13 401+239 18 167+28 0.254
Figure 2 Idebenone signiﬁcantly improves wheel running performance in mdx mice. Voluntary wheel running performance (mean+standard
error) in vehicle-treated wild-type, vehicle-treated mdx, and idebenone-treated mdx mice. (A) Average daily running distance. (B) Cumulative
daily running distance. (C) Speed of running. (D) Running distance at high speed. ANOVA and pairwise comparisons showed signiﬁcant differ-
ences between all groups as well as between mdx vehicle and mdx idebenone groups (P , 0.001) for the analyses presented in (A), (C), and (D).
Data shown in (B) is a different graphical representation of the data shown in (A).
Study of SNT-MC17/idebenone in mdx mouse 123radicals contribute to the pathophysiology.
21–23 Idebenone
(2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone)
has been shown to act as membrane-associated antioxidant that
can prevent the formation of reactive oxygen species and reactive
radicals.
6–7,24 Idebenone inhibits lipid peroxidation which protects
cell membranes and mitochondria from oxidative damage. The
molecule’s optimized physicochemical properties favour uptake
into cells and allow the incorporation into the mitochondrial mem-
brane where it can facilitate the ﬂux of electrons along the mito-
chondrial electron transport chain and increase cellular energy
output which in turn protects mitochondria from malfunction
and improves cellular survival.
25
In conclusion, presymptomatic-initiated and long-term treat-
ment with idebenone was cardioprotective and improved
running performance in the dystrophin-deﬁcient mdx mouse. We
have therefore identiﬁed a novel potential therapeutic strategy
for the homologous human DMD, a currently untreatable
disease where the associated cardiomyopathy is responsible for
early death of 40% of patients. Our results therefore encourage
studies with idebenone in human DMD patients. Such studies will
also provide answers to the important question whether thera-
peutic studies in a homologous mouse model can be predictive
for the human dystrophin-deﬁcient situation. If so, our current
study will gain further signiﬁcance by demonstrating that the mdx
mouse does provide unique opportunities for long-term con-
trolled ‘prehuman’ therapeutic studies. Apart from its therapeutic
ﬁndings, our study shows at a clinical level cardiac and motor def-
icits in the dystrophic mouse, and as such contributes to bridging
the gap between laboratory scientists and clinicians in the ﬁeld
of muscular dystrophy.
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